Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The pilot PARTUM trial is a randomized, multicenter, placebo-controlled trial. Women who are
at modest risk of VTE (as defined by the inclusion criteria) will be identified during
pregnancy, labor and delivery and up to 48 hours postpartum. Eligible and consenting
participants will be randomly assigned to one of two study arms: aspirin 81 mg daily or
placebo daily for 6 weeks.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Calgary
Collaborators:
Canadian Institutes of Health Research (CIHR) Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network